Pharmacokinetics of Antisense Oligonucleotides View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1995-01

AUTHORS

Sudhir Agrawal, Jamal Temsamani, Wayne Galbraith, Jinyan Tang

ABSTRACT

Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases.Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes. Administration of a single dose of the phosphorothioate (S-oligonucleotide) in animals by the intravenous route reveals biphasic plasma elimination. An initial short half-life (0.53 to 0.83 hours) represents distribution out of the plasma compartment and a second long half-life (35 to 50 hours) represents elimination from the body. This elimination half-life was similar when the oligonucleotide was administered subcutaneously. In contrast, methylphosphonate oligonucleotides have an elimination half-life of 17 minutes in mice.S-Oligonucleotide was distributed into most of organs of rats and mice. Liver and kidney were the 2 organs with highest uptake of the oligonucleotide. The S-oligonucleotide was primarily excreted in urine. Up to 30% was excreted in the first 24 hours.Repeated daily intravenous injections of a 25-mer S-oligonucleotide into rats showed that the concentrations in the plasma are at steady-state during the 8 days’ administration.The data represented here support the potential utility of phosphorothioate and methylphosphonate oligonucleotides as therapeutic agents in vivo. More... »

PAGES

7-16

Journal

TITLE

Clinical Pharmacokinetics

ISSUE

1

VOLUME

28

Related Patents

  • Immunostimulatory Nucleic Acid Molecules
  • Immunostimulatory Nucleic Acids
  • Oligonucleotides Having A '5tcg Motif Without Any Additional Unmethylated Cpg Motifs Have Strong Immunostimulatory Capability
  • Nucleotide Vector Composition Containing Such Vector And Vaccine For Immunization Against Hepatitis
  • Cpg Oligonucleotide Analogs Containing Hydrophobic T Analogs With Enhanced Immunostimulatory Activity
  • For Treatment Of Atopic Conditions (Dermatitis, Allergies) And Influenza Virus; Point Mutations
  • Modified Protein Kinase A-Specific Oligonucleotides And Methods Of Their Use
  • Semi-Soft C-Class Immunostimulatory Oligonucleotides
  • Using Oligonucleotide/Delivery Complexes To Enhance Immune Response Via Increase Interferon Concentration; Antisense Therapies; Gene Expression Inhibition; Viricides
  • Cpg Oligonucleotide Analogs Containing Hydrophobic T Analogs With Enhanced Immunostimulatory Activity
  • Immunostimulatory Nucleic Acid Molecules
  • Method Of Inducing An Antigen-Specific Immune Response By Administering A Synergistic Combination Of Adjuvants Comprising Unmethylated Cpg-Containing Nucleic Acids And A Non-Nucleic Acid Adjuvant
  • Immunostimulatory Nucleic Acid Molecules
  • Synergistic Mixtures; Hepatitis Virus
  • Immunostimulatory Nucleic Acids
  • Methods And Products Related To Treatment And Prevention Of Hepatitis C Virus Infection
  • Cpg Oligonucleotide Analogs Containing Hydrophobic T Analogs With Enhanced Immunostimulatory Activity
  • Immune Stimulation By Phosphorothioate Oligonucleotide Analogs
  • Immunostimulatory Nucleic Acid Molecules
  • Containing Unmethylated Cpg Dinucleotides; Redirection Of A Th2 Response To A Th1 Response; Atopic Diseases, Dermatitis
  • For Treatment Of Atopic Conditions (Dermatitis, Allergies); Point Mutations; Immunotherapy
  • Nucleic Acids Containing Unmethylated Cytosine-Guanine Dinucleotides Activate Lymphocytes And Redirect An Immune Response From Th2 To Th1
  • Modulate Immunology Response; Asthma Therapy; Autoimmune Disease
  • Methods And Products For Inducing Mucosal Immunity
  • Modified Protein Kinase A-Specific Oligonucleotides And Methods Of Their Use
  • Nucleotide Vector Vaccine For Immunization Against Hepatitis
  • Semi-Soft C-Class Immunostimulatory Oligonucleotides
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00003088-199528010-00002

    DOI

    http://dx.doi.org/10.2165/00003088-199528010-00002

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1047632676

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/7712663


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antiviral Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Base Sequence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Clinical Trials as Topic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Esters", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Molecular Sequence Data", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligodeoxyribonucleotides, Antisense", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oligonucleotides, Antisense", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Organophosphorus Compounds", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Thionucleotides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tissue Distribution", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Agrawal", 
            "givenName": "Sudhir", 
            "id": "sg:person.01124454740.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Temsamani", 
            "givenName": "Jamal", 
            "id": "sg:person.0703710210.14", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703710210.14"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "ADP Company, Arlington, Virginia, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "ADP Company, Arlington, Virginia, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Galbraith", 
            "givenName": "Wayne", 
            "id": "sg:person.01320131174.92", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320131174.92"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tang", 
            "givenName": "Jinyan", 
            "id": "sg:person.015173645364.51", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015173645364.51"
            ], 
            "type": "Person"
          }
        ], 
        "datePublished": "1995-01", 
        "datePublishedReg": "1995-01-01", 
        "description": "Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases.Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes. Administration of a single dose of the phosphorothioate (S-oligonucleotide) in animals by the intravenous route reveals biphasic plasma elimination. An initial short half-life (0.53 to 0.83 hours) represents distribution out of the plasma compartment and a second long half-life (35 to 50 hours) represents elimination from the body. This elimination half-life was similar when the oligonucleotide was administered subcutaneously. In contrast, methylphosphonate oligonucleotides have an elimination half-life of 17 minutes in mice.S-Oligonucleotide was distributed into most of organs of rats and mice. Liver and kidney were the 2 organs with highest uptake of the oligonucleotide. The S-oligonucleotide was primarily excreted in urine. Up to 30% was excreted in the first 24 hours.Repeated daily intravenous injections of a 25-mer S-oligonucleotide into rats showed that the concentrations in the plasma are at steady-state during the 8 days\u2019 administration.The data represented here support the potential utility of phosphorothioate and methylphosphonate oligonucleotides as therapeutic agents in vivo.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00003088-199528010-00002", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1085321", 
            "issn": [
              "0312-5963", 
              "1179-1926"
            ], 
            "name": "Clinical Pharmacokinetics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "28"
          }
        ], 
        "keywords": [
          "intravenous injection", 
          "therapeutic agents", 
          "daily intravenous injections", 
          "S-oligonucleotide", 
          "organs of rats", 
          "life-threatening disease", 
          "single dose", 
          "plasma elimination", 
          "intravenous route", 
          "day administration", 
          "plasma compartment", 
          "administration", 
          "high uptake", 
          "rats", 
          "mice", 
          "potential utility", 
          "injection", 
          "organs", 
          "minutes", 
          "pharmacokinetics of antisense", 
          "pharmacokinetics", 
          "agents", 
          "kidney", 
          "disease", 
          "elimination", 
          "liver", 
          "dose", 
          "urine", 
          "monkeys", 
          "treatment", 
          "plasma", 
          "vivo", 
          "animals", 
          "hours", 
          "antisense", 
          "uptake", 
          "compartments", 
          "contrast", 
          "utility", 
          "oligonucleotide", 
          "body", 
          "concentration", 
          "phosphorothioate", 
          "analogues", 
          "data", 
          "oligonucleotide analogues", 
          "route", 
          "distribution"
        ], 
        "name": "Pharmacokinetics of Antisense Oligonucleotides", 
        "pagination": "7-16", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1047632676"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00003088-199528010-00002"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "7712663"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00003088-199528010-00002", 
          "https://app.dimensions.ai/details/publication/pub.1047632676"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:51", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_280.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00003088-199528010-00002"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003088-199528010-00002'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003088-199528010-00002'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003088-199528010-00002'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003088-199528010-00002'


     

    This table displays all metadata directly associated to this object as RDF triples.

    184 TRIPLES      20 PREDICATES      87 URIs      79 LITERALS      20 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00003088-199528010-00002 schema:about N068daee245b7489db30219422fcc1b6d
    2 N06c315ab97094641bc1120569579d95d
    3 N1722d7a21119486ab6d92297162dcd55
    4 N19fbe800e2ba40b5bd296818651ea804
    5 N1d3229796f9b4a8eb26b2441642f4d25
    6 N3339601782f74310af26118b5b8b3d53
    7 N3f383bdf75084c0f8eb817644cb52282
    8 N5edbc3f78a914fcbaf34077455ede256
    9 Nb41bbf59b553407cb637bc2e908d5cf3
    10 Nb82e55c7c1534241924c6b816a1ed21b
    11 Nb9870bfd78aa47468b7212e55cc6a9da
    12 Nef3863548e95424c97f185806825ef63
    13 Nf407d187be25403ea4b62e6c59c60269
    14 anzsrc-for:11
    15 anzsrc-for:1115
    16 schema:author N16efa9d76a764d098879a247c74a5754
    17 schema:datePublished 1995-01
    18 schema:datePublishedReg 1995-01-01
    19 schema:description Antisense oligonucleotides are promising therapeutic agents for the treatment of life-threatening diseases.Intravenous injection of phosphodiester oligonucleotide analogue (P-oligonucleotide) in monkeys shows that the oligonucleotide is degraded rapidly in the plasma with a half-life of about 5 minutes. Administration of a single dose of the phosphorothioate (S-oligonucleotide) in animals by the intravenous route reveals biphasic plasma elimination. An initial short half-life (0.53 to 0.83 hours) represents distribution out of the plasma compartment and a second long half-life (35 to 50 hours) represents elimination from the body. This elimination half-life was similar when the oligonucleotide was administered subcutaneously. In contrast, methylphosphonate oligonucleotides have an elimination half-life of 17 minutes in mice.S-Oligonucleotide was distributed into most of organs of rats and mice. Liver and kidney were the 2 organs with highest uptake of the oligonucleotide. The S-oligonucleotide was primarily excreted in urine. Up to 30% was excreted in the first 24 hours.Repeated daily intravenous injections of a 25-mer S-oligonucleotide into rats showed that the concentrations in the plasma are at steady-state during the 8 days’ administration.The data represented here support the potential utility of phosphorothioate and methylphosphonate oligonucleotides as therapeutic agents in vivo.
    20 schema:genre article
    21 schema:isAccessibleForFree false
    22 schema:isPartOf N2221362935ef47e1b18312e066cc6d88
    23 N9a0f59eae2a444cb8ce0dedee6f75fbd
    24 sg:journal.1085321
    25 schema:keywords S-oligonucleotide
    26 administration
    27 agents
    28 analogues
    29 animals
    30 antisense
    31 body
    32 compartments
    33 concentration
    34 contrast
    35 daily intravenous injections
    36 data
    37 day administration
    38 disease
    39 distribution
    40 dose
    41 elimination
    42 high uptake
    43 hours
    44 injection
    45 intravenous injection
    46 intravenous route
    47 kidney
    48 life-threatening disease
    49 liver
    50 mice
    51 minutes
    52 monkeys
    53 oligonucleotide
    54 oligonucleotide analogues
    55 organs
    56 organs of rats
    57 pharmacokinetics
    58 pharmacokinetics of antisense
    59 phosphorothioate
    60 plasma
    61 plasma compartment
    62 plasma elimination
    63 potential utility
    64 rats
    65 route
    66 single dose
    67 therapeutic agents
    68 treatment
    69 uptake
    70 urine
    71 utility
    72 vivo
    73 schema:name Pharmacokinetics of Antisense Oligonucleotides
    74 schema:pagination 7-16
    75 schema:productId N4bedb241c6c54165b0f0a4afb8cbe79e
    76 Nb26b469e997442b6b34e88f91e91f87d
    77 Nf132806277434e45b55b5bcfa0c5abfe
    78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047632676
    79 https://doi.org/10.2165/00003088-199528010-00002
    80 schema:sdDatePublished 2022-08-04T16:51
    81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    82 schema:sdPublisher N2be9a35e352d41a58d358c726c0daa47
    83 schema:url https://doi.org/10.2165/00003088-199528010-00002
    84 sgo:license sg:explorer/license/
    85 sgo:sdDataset articles
    86 rdf:type schema:ScholarlyArticle
    87 N068daee245b7489db30219422fcc1b6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    88 schema:name Molecular Sequence Data
    89 rdf:type schema:DefinedTerm
    90 N06c315ab97094641bc1120569579d95d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    91 schema:name Antiviral Agents
    92 rdf:type schema:DefinedTerm
    93 N1655b9d5f34847f6b1430391cdc2f3db rdf:first sg:person.0703710210.14
    94 rdf:rest Nc831a8cfa6fe403380dff6108bd3d364
    95 N16efa9d76a764d098879a247c74a5754 rdf:first sg:person.01124454740.04
    96 rdf:rest N1655b9d5f34847f6b1430391cdc2f3db
    97 N1722d7a21119486ab6d92297162dcd55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Humans
    99 rdf:type schema:DefinedTerm
    100 N19fbe800e2ba40b5bd296818651ea804 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Esters
    102 rdf:type schema:DefinedTerm
    103 N1d3229796f9b4a8eb26b2441642f4d25 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Clinical Trials as Topic
    105 rdf:type schema:DefinedTerm
    106 N2221362935ef47e1b18312e066cc6d88 schema:issueNumber 1
    107 rdf:type schema:PublicationIssue
    108 N2be9a35e352d41a58d358c726c0daa47 schema:name Springer Nature - SN SciGraph project
    109 rdf:type schema:Organization
    110 N3339601782f74310af26118b5b8b3d53 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    111 schema:name Organophosphorus Compounds
    112 rdf:type schema:DefinedTerm
    113 N3f383bdf75084c0f8eb817644cb52282 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Thionucleotides
    115 rdf:type schema:DefinedTerm
    116 N4bedb241c6c54165b0f0a4afb8cbe79e schema:name pubmed_id
    117 schema:value 7712663
    118 rdf:type schema:PropertyValue
    119 N5edbc3f78a914fcbaf34077455ede256 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    120 schema:name Oligodeoxyribonucleotides, Antisense
    121 rdf:type schema:DefinedTerm
    122 N9a0f59eae2a444cb8ce0dedee6f75fbd schema:volumeNumber 28
    123 rdf:type schema:PublicationVolume
    124 Nb26b469e997442b6b34e88f91e91f87d schema:name doi
    125 schema:value 10.2165/00003088-199528010-00002
    126 rdf:type schema:PropertyValue
    127 Nb41bbf59b553407cb637bc2e908d5cf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Tissue Distribution
    129 rdf:type schema:DefinedTerm
    130 Nb82e55c7c1534241924c6b816a1ed21b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Oligonucleotides
    132 rdf:type schema:DefinedTerm
    133 Nb9870bfd78aa47468b7212e55cc6a9da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    134 schema:name Animals
    135 rdf:type schema:DefinedTerm
    136 Nc831a8cfa6fe403380dff6108bd3d364 rdf:first sg:person.01320131174.92
    137 rdf:rest Nf08876ba63364998b66ab173e559c653
    138 Nef3863548e95424c97f185806825ef63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Oligonucleotides, Antisense
    140 rdf:type schema:DefinedTerm
    141 Nf08876ba63364998b66ab173e559c653 rdf:first sg:person.015173645364.51
    142 rdf:rest rdf:nil
    143 Nf132806277434e45b55b5bcfa0c5abfe schema:name dimensions_id
    144 schema:value pub.1047632676
    145 rdf:type schema:PropertyValue
    146 Nf407d187be25403ea4b62e6c59c60269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Base Sequence
    148 rdf:type schema:DefinedTerm
    149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    150 schema:name Medical and Health Sciences
    151 rdf:type schema:DefinedTerm
    152 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    153 schema:name Pharmacology and Pharmaceutical Sciences
    154 rdf:type schema:DefinedTerm
    155 sg:journal.1085321 schema:issn 0312-5963
    156 1179-1926
    157 schema:name Clinical Pharmacokinetics
    158 schema:publisher Springer Nature
    159 rdf:type schema:Periodical
    160 sg:person.01124454740.04 schema:affiliation grid-institutes:None
    161 schema:familyName Agrawal
    162 schema:givenName Sudhir
    163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04
    164 rdf:type schema:Person
    165 sg:person.01320131174.92 schema:affiliation grid-institutes:None
    166 schema:familyName Galbraith
    167 schema:givenName Wayne
    168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320131174.92
    169 rdf:type schema:Person
    170 sg:person.015173645364.51 schema:affiliation grid-institutes:None
    171 schema:familyName Tang
    172 schema:givenName Jinyan
    173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015173645364.51
    174 rdf:type schema:Person
    175 sg:person.0703710210.14 schema:affiliation grid-institutes:None
    176 schema:familyName Temsamani
    177 schema:givenName Jamal
    178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703710210.14
    179 rdf:type schema:Person
    180 grid-institutes:None schema:alternateName ADP Company, Arlington, Virginia, USA
    181 Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA
    182 schema:name ADP Company, Arlington, Virginia, USA
    183 Hybridon Inc., 1 Innovation Drive, 01605, Worcester, Massachusetts, USA
    184 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...